|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Calcagno DQ, de Arruda Cardoso Smith M and
Burbano RR: Cancer type-specific epigenetic changes: Gastric
cancer. Methods Mol Biol. 1238:79–101. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cheah IK, Lei F, Tang RMY, Lim KHC and
Halliwell B: Ergothioneine levels in an elderly population decrease
with age and incidence of cognitive decline; a risk factor for
neurodegeneration? Biochem Biophys Res Commun. 478:162–167. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Subramanya MS, Hossain MB, Khan S, Memon B
and Memon MA: Meta-analysis of D1 versus D2 gastrectomy for gastric
adenocarcinoma. Islamic Countries Conferecne on Statistical
Sciences. 2009.
|
|
5
|
Conteduca V, Sansonno D, Lauletta G, Russi
S, Ingravallo G and Dammacco F: H. pylori infection and gastric
cancer: State of the art (review). Int J Oncol. 42:5–18. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Venerito M, Vasapolli R, Rokkas T,
Delchier JC and Malfertheiner P: Helicobacter pylori,
gastric cancer and other gastrointestinal malignancies.
Helicobacter. 22 Suppl 1:2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sarker KK, Kabir MJ, Bhuyian AKMMU, Alam
MS, Chowdhury FR, Ahad MA, Rahman MA and Rahman MM: H. pylori
infection and gastric cancer in Bangladesh: A case-control study.
Int J Surg Oncol (N Y). 2:e442017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Grabsch HI and Tan P: Gastric cancer
pathology and underlying molecular mechanisms. Dig Surg.
30:150–158. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Canu V, Sacconi A, Lorenzon L, Biagioni F,
Lo Sardo F, Diodoro MG, Muti P, Garofalo A, Strano S, D'Errico A,
et al: MiR-204 down-regulation elicited perturbation of a gene
target signature common to human cholangiocarcinoma and gastric
cancer. Oncotarget. 8:29540–29557. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Abbas M, Habib M, Naveed M, Karthik K,
Dhama K, Shi M and Dingding C: The relevance of gastric cancer
biomarkers in prognosis and pre- and post-chemotherapy in clinical
practice. Biomed Pharmacother. 95:1082–1090. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gong F, Hou G, Liu H and Zhang M:
Peroxiredoxin 1 promotes tumorigenesis through regulating the
activity of mTOR/p70S6K pathway in esophageal squamous cell
carcinoma. Med Oncol. 32:4552015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Choi H, Chang JW and Jung YK:
Peroxiredoxin 6 interferes with TRAIL-induced death-inducing
signaling complex formation by binding to death effector domain
caspase. Cell Death Differ. 18:405–414. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Perkins A, Poole LB and Karplus PA: Tuning
of peroxiredoxin catalysis for various physiological roles.
Biochemistry. 53:7693–7705. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nyström T, Yang J and Molin M:
Peroxiredoxins, gerontogenes linking aging to genome instability
and cancer. Genes Dev. 26:2001–2008. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lehtonen ST, Svensk AM, Soini Y, Pääkkö P,
Hirvikoski P, Sang WK, Säily M and Kinnula VL: Peroxiredoxins, a
novel protein family in lung cancer. Int J Cancer. 111:514–521.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Soini Y, Kallio JP, Hirvikoski P, Helin H,
Kellokumpu-Lehtinen P, Kang SW, Tammela TL, Peltoniemi M,
Martikainen PM and Kinnula VL: Oxidative/nitrosative stress and
peroxiredoxin 2 are associated with grade and prognosis of human
renal carcinoma. APMIS. 114:329–337. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu Y and Zhou BP: Epithelial-Mesenchymal
Transition in Development and Diseases. Springer; New York:
2009
|
|
18
|
Petrova YI, Schecterson L and Gumbiner BM:
Roles for E-cadherin cell surface regulation in cancer. Mol Biol
Cell. 27:3233–3244. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xian X, Huang L, Zhang B, Wu C, Cui J and
Wang Z: WIN 55,212-2 inhibits the epithelial mesenchymal transition
of gastric cancer cells via COX-2 signals. Cell Physiol Biochem.
39:2149–2157. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lv Z, Weng X, Du C, Zhang C, Xiao H, Cai
X, Ye S, Cheng J, Ding C, Xie H, et al: Downregulation of HDAC6
promotes angiogenesis in hepatocellular carcinoma cells and
predicts poor prognosis in liver transplantation patients. Mol
Carcinog. 55:1024–1033. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ow SH, Chua PJ and Bay BH: Epigenetic
regulation of peroxiredoxins: Implications in the pathogenesis of
cancer. Exp Biol Med (Maywood). 242:140–147. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rhee SG, Chae HZ and Kim K:
Peroxiredoxins: A historical overview and speculative preview of
novel mechanisms and emerging concepts in cell signaling. Free
Radic Biol Med. 38:1543–1552. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim H, Lee TH, Park ES, Suh JM, Park SJ,
Chung HK, Kwon OY, Kim YK, Ro HK and Shong M: Role of
peroxiredoxins in regulating intracellular hydrogen peroxide and
hydrogen peroxide-induced apoptosis in thyroid cells. J Biol Chem.
275:18266–18270. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kang SW, Chae HZ, Seo MS, Kim K, Baines IC
and Rhee SG: Mammalian peroxiredoxin isoforms can reduce hydrogen
peroxide generated in response to growth factors and tumor necrosis
factor-alpha. J Biol Chem. 273:6297–6302. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Choi MH, Lee IK, Kim GW, Kim BU, Han YH,
Yu DY, Park HS, Kim KY, Lee JS, Choi C, et al: Regulation of PDGF
signalling and vascular remodelling by peroxiredoxin II. Nature.
435:347–353. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kwon J, Devadas S and Williams MS: T cell
receptor-stimulated generation of hydrogen peroxide inhibits
MEK-ERK activation and lck serine phosphorylation. Free Radic Biol
Med. 35:406–417. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kang DH, Lee DJ, Lee KW, Park YS, Lee JY,
Lee SH, Koh YJ, Koh GY, Choi C, Yu DY, et al: Peroxiredoxin II Is
an essential antioxidant enzyme that prevents the oxidative
inactivation of VEGF receptor-2 in vascular endothelial cells. Mol
Cell. 44:545–558. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Park YH, Kim SU, Kwon TH, Kim JM, Song IS,
Shin HJ, Lee BK, Bang DH, Lee SJ, Lee DS, et al: Peroxiredoxin II
promotes hepatic tumorigenesis through cooperation with Ras
Forkhead box M1 signaling pathway. Oncogene. 35:3503–3513. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Karihtala P, Mäntyniemi A, Kang SW,
Kinnula VL and Soini Y: Peroxiredoxins in breast carcinoma. Clin
Cancer Res. 9:3418–3424. 2003.PubMed/NCBI
|
|
31
|
Lehtonen ST, Markkanen PM, Peltoniemi M,
Kang SW and Kinnula VL: Variable overoxidation of peroxiredoxins in
human lung cells in severe oxidative stress. Am J Physiol Lung Cell
Mol Physiol. 288:L997–L1001. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang WJ and Zou XY: Influence of
cilazapril and taurine on apoptosis of chronic hypoxic lung tissue.
Chin J Patho. 1999.
|
|
33
|
Marengo B, Nitti M, Furfaro AL, Colla R,
Ciucis CD, Marinari UM, Pronzato MA, Traverso N and Domenicotti C:
Redox homeostasis and cellular antioxidant systems: crucial players
in cancer growth and therapy. Oxid Med Cell Longev.
2016:62356412016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang T, Diaz AJ and Yen Y: The role of
peroxiredoxin II in chemoresistance of breast cancer cells. Breast
Cancer (Dove Med Press). 6:73–80. 2014.PubMed/NCBI
|
|
35
|
Ward E: Cancer statistics, 2010. Ca A
Cancer J Clin. 62:10–29. 2012.
|
|
36
|
Kim H, Yoo SB, Sun P, Jin Y, Jheon S, Lee
CT and Chung JH: Alteration of the E-Cadherin/β-Catenin Complex Is
an Independent Poor Prognostic Factor in Lung Adenocarcinoma.
Korean J Pathol. 47:44–51. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Brabletz T, Hlubek F, Spaderna S,
Schmalhofer O, Hiendlmeyer E, Jung A and Kirchner T: Invasion and
metastasis in colorectal cancer: epithelial-mesenchymal transition,
mesenchymal-epithelial transition, stem cells and beta-catenin.
Cells Tissues Organs. 179:56–65. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mook OR, Frederiks WM and Van Noorden CJ:
The role of gelatinases in colorectal cancer progression and
metastasis. Biochim Biophys Acta. 1705:69–89. 2004.PubMed/NCBI
|
|
39
|
Lu W, Fu Z, Wang H, Feng J, Wei J and Guo
J: Peroxiredoxin 2 knockdown by RNA interference inhibits the
growth of colorectal cancer cells by downregulating Wnt/β-catenin
signaling. Cancer Lett. 343:190–199. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Leak RK, Zhang L, Luo Y, Li P, Zhao H, Liu
X, Ling F, Jia J, Chen J and Ji X: Peroxiredoxin 2 battles
poly(ADP-ribose) polymerase 1- and p53-dependent prodeath pathways
after ischemic injury. Stroke. 44:1124–1134. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu SL, Shi DY, Pan XH and Shen ZH:
Inhibition of proliferation and expression of N-ras in hepatoma
cells by antioxidation treatment. Sheng Wu Hua Xue Yu Sheng Wu Wu
Li Xue Bao (Shanghai). 33:463–466. 2001.PubMed/NCBI
|
